A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)

Trial Profile

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Omaveloxolone (Primary)
  • Indications Mitochondrial myopathies
  • Focus Therapeutic Use
  • Acronyms MOTOR
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 03 Mar 2017 According to a Reata Pharmaceuticals media release, data from this first part of this trial are expected in the second half of 2017.
    • 14 Nov 2016 Planned number of patients changed from 56 to 100.
    • 11 Aug 2016 According to a Reata Pharmaceuticals media release, initial data from this trial are expected in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top